Actavis Joins the Divestment Bandwagon - Analyst Blog

Comment

Shutterstock photo

Actavis ( ACT ) has received a binding offer for its generics commercial operations in seven Western European countries (France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands) from India-based Aurobindo Pharma Limited. Total value of the deal is expected to be €30 million.

If the deal goes through, Aurobindo Pharma will acquire Actavis' pharmaceutical commercial infrastructure including personnel, commercial infrastructure, products, marketing authorizations and dossier licenses in the covered countries. Aurobindo Pharma estimates that the net sales of the acquired businesses will be approximately €320 million in 2013, representing an increase of more than 10% from the year ago period. The companies will also enter into a supply agreement.

The divestment will allow Actavis to focus more on its core and higher growth areas (including Central and Eastern Europe and Southeast Asia). We are positive on the potential deal.

Industry-Wide Trend

We note that Actavis is not the only company focusing on its core assets and divesting (or planning to divest) its non-core assets to drive growth. Several other big pharma companies have either divested or entered into agreements to divest their non core assets. For example, GlaxoSmithKline ( GSK ) divested several non-core brands from its Consumer Healthcare segment and Johnson & Johnson ( JNJ ) recently received a binding offer for its Ortho-Clinical Diagnostics (OCD) business.

In the near term, we believe that investor focus will remain on Actavis' release of fourth quarter and full year 2013 results (Feb 20). Actavis expects fourth quarter 2013 adjusted earnings to be slightly above the high end of the previously issued guidance of $2.95-$3.05 per share.

The Zacks Consensus Estimate currently stands at $3.02, well below the company's guidance. We expect to see significant upward revisions in earnings estimates for the fourth quarter and full year 2013.

Actavis carries a Zacks Rank #1 (Strong Buy). Other stocks which look attractive at current levels include Actelion Ltd. ( ALIOF ). The stock carries the same Zacks Rank as Actavis.



ACTAVIS PLC (ACT): Free Stock Analysis Report

ACTELION LTD (ALIOF): Get Free Report

GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Business , Stocks
More Headlines for: ACT , ALIOF , GSK , JNJ


More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com